Use the hyperlinks, where available to access additional clinical trial information.
Phase II Single Arm Study evaluating safety, feasibility and efficacy of Ipilimumab and Nivolumab with neoadjuvant weekly Paclitaxel after Anthracycline based chemotherapy in High-risk primary Triple Negative Breast Cancer, followed by definite surgery and completion of 1 year total duration of Nivolumab
Australian New Zealand Breast Cancer Trials Group (ANZBCTG)
Before surgery, patients will receive the following treatments, simultaneously, over a 12 week period -
Intravenous Nivolumab at 3mg/kg every 2 weeks for 6 doses; Intravenous Ipilimumab at 1mg/kg every 6 weeks for 2 doses; and Intravenous Paclitaxel at 80mg/m^2 for 12 doses. Where administration of the study drugs occur on the same day, Nivolumab is given first, Ipilimumab second and Paclitaxel last.
Surgery will take place within 4 weeks of the last paclitaxel dose.
Participants will recommence Nivolumab 2-6 weeks after surgery as determined by the investigator.
Not currently recruiting